Silexion Therapeutics

The SPAC combination materially increased cash and repaired the balance sheet, providing near‑term runway to advance the pipeline without immediate insolvency risk. If true, management can fund R&D milestones and attract partners; if false, forced dilutive financing or insolvency will destroy equity value.

Current operating cash outflows are large relative to cash on hand, so absent meaningful revenue or partnership income Silexion will need to raise additional capital to continue development. Need for financing will determine dilution risk and timing of value realization; successful non‑dilutive deals preserve upside while equity raises compress returns.

Because product revenue is effectively nil, Silexion’s enterprise value will be driven by clinical and licensing milestones (IND filings, trial initiations/readouts, partnerships) rather than recurring sales. Investors must treat the stock as binary and milestone‑driven; absence of milestone progress will not be masked by revenue growth in the near term.

The post‑combination improvement in assets, liabilities and equity reduces immediate solvency risk but is temporary unless matched by either milestone revenue, partnerships, or significant reductions in cash burn. A temporary balance-sheet fix without operational improvement only delays inevitable financing and potential dilution; conversely, converting the temporary buffer into milestones preserves equity value.